A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...
A long-standing request to clarify data irregularities in a 2021 ISCHEMIA substudy resulted in the publication of one correction, with a second correction in the works. Further, the lone cardiac ...
CHICAGO, IL—When patients stop taking oral anticoagulation (OAC) after they’ve been free of atrial fibrillation (AF) ...
New findings from a DETOUR2 substudy show that minimally invasive percutaneous transmural arterial bypass (PTAB) may offer a ...
BASKING RIDGE, N.J. -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced the presentation of two posters ...
Please provide your email address to receive an email when new articles are posted on . In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ...
The goal of the substudy is to evaluate the safety of biweekly IV Trappsol ® Cyclo™ (HPβCD) (2000 mg/kg) for 192 weeks in very young patients (birth to ≤ 3 years), in order to obtain descriptive data ...
Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results